NCT04557215View on ClinicalTrials.gov

Efficacy and Safety of Rifaximin With NAC in IBS-D

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

November 13, 2020

Primary Completion Date

August 31, 2021

Study Completion Date

October 30, 2022

Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
DRUG

Rifaximin

Rifaximin is indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

DRUG

N-acetylcysteine

N-acetylcysteine (NAC) is a clinically approved mucolytic agent.

DRUG

Placebo

An inactive substance or treatment that looks the same as, and is given in the same way as, an active drug or intervention/treatment being studied.

Trial Locations (1)

90048

Cedars-Sinai Medical Center, Los Angeles

All Listed Sponsors
collaborator

Bausch Health Ireland Limited

INDUSTRY

lead

Cedars-Sinai Medical Center

OTHER

NCT04557215 - Efficacy and Safety of Rifaximin With NAC in IBS-D | Biotech Hunter | Biotech Hunter